Insmed (MIL:1INSM) Cyclically Adjusted Book per Share: €2.52 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1INSM Insmed Inc MIL:1INSM
45 GF Score
Price €86.10
GF Value €160.63
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Insmed Cyclically Adjusted Book per Share?

Insmed MIL:1INSM 45 Cyclically Adjusted Book per Share is €2.52 as of Mar. 2026. GuruFocus rates MIL:1INSM with a GF Score™ of 45/100 and a GF Value™ of €160.63 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Insmed's adjusted book value per share for the three months ended in Mar. 2026 was €2.816. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €2.52 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Insmed's average Cyclically Adjusted Book Growth Rate was -6.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -9.40% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -8.10% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -5.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Insmed was 5.60% per year. The lowest was -17.60% per year. And the median was -7.35% per year.

As of today (2026-08-06), Insmed's current stock price is €86.10. Insmed's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €2.52. Insmed's Cyclically Adjusted PB Ratio of today is 34.17.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Insmed was 67.68. The lowest was 2.56. And the median was 6.48.


Insmed  (MIL:1INSM) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Insmed's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=86.10/2.52
=34.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Insmed was 67.68. The lowest was 2.56. And the median was 6.48.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Insmed Cyclically Adjusted Book per Share Related Terms


Insmed Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Insmed's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insmed Cyclically Adjusted Book per Share Chart

Insmed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 2.43

Insmed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 2.63 2.64 2.43 2.52

MIL:1INSM vs INCY, BNTX, MRNA: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Insmed's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insmed Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Insmed's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Insmed's Cyclically Adjusted PB Ratio falls into.


MIL:1INSM
45GF Score
Insmed Inc MIL:1INSM
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insmed Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Insmed's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.816/330.2130*330.2130
=2.816

Current CPI (Mar. 2026) = 330.2130.

Insmed Quarterly Data

Book Value per Share CPI Adj_Book
201606 3.604 241.018 4.938
201609 3.137 241.428 4.291
201612 2.361 241.432 3.229
201703 1.832 243.801 2.481
201706 1.191 244.955 1.606
201709 4.616 246.819 6.176
201712 3.982 246.524 5.334
201803 4.603 249.554 6.091
201806 4.118 251.989 5.396
201809 3.240 252.439 4.238
201812 2.368 251.233 3.112
201903 1.644 254.202 2.136
201906 3.537 256.143 4.560
201909 3.091 256.759 3.975
201912 2.626 256.974 3.374
202003 2.082 258.115 2.664
202006 3.548 257.797 4.545
202009 2.978 260.280 3.778
202012 2.207 260.474 2.798
202103 1.640 264.877 2.045
202106 3.825 271.696 4.649
202109 3.626 274.310 4.365
202112 3.059 278.802 3.623
202203 0.912 287.504 1.047
202206 0.349 296.311 0.389
202209 -0.249 296.808 -0.277
202212 0.612 296.797 0.681
202303 -0.306 301.836 -0.335
202306 -1.007 305.109 -1.090
202309 -1.895 307.789 -2.033
202312 -2.057 306.746 -2.214
202403 -2.878 312.332 -3.043
202406 0.216 314.175 0.227
202409 2.435 315.301 2.550
202412 1.519 315.605 1.589
202503 0.504 319.799 0.520
202506 5.132 322.561 5.254
202509 3.790 324.800 3.853
202512 2.945 324.054 3.001
202603 2.816 330.213 2.816

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €2.52 mean?
Insmed (MIL:1INSM) has a Cyclically Adjusted Book per Share of €2.52 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Insmed and its competitors.
Is Insmed's Cyclically Adjusted Book per Share too high?
Insmed's current Cyclically Adjusted Book per Share is €2.52. Overall, Insmed has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Insmed's Cyclically Adjusted Book per Share compare to INCY and BNTX?
Insmed's Cyclically Adjusted Book per Share of €2.52 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Insmed and its competitors. Insmed's current Cyclically Adjusted Book per Share is €2.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Based on GuruFocus' analysis, Insmed (MIL:1INSM) is currently considered Possible Value Trap. The stock's GF Value™ is €160.63, compared to a current price of €86.10 — trading 46.4% below its estimated fair value. The current Cyclically Adjusted Book per Share is €2.52. Insmed's overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Insmed (MIL:1INSM), the current Cyclically Adjusted Book per Share is €2.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insmed (MIL:1INSM) Overvalued in 2026?

Based on GuruFocus' analysis, Insmed stock appears to be undervalued. The current stock price of €86.10 is trading 46.4% below its estimated GF Value™ of €160.63. GuruFocus considers Insmed to be Possible Value Trap.

Key valuation signals for MIL:1INSM:

  • Cyclically Adjusted Book per Share: €2.52
  • GF Value™: €160.63 vs. price of €86.10 (46.4% below fair value)
  • GF Score™: 45/100 with 4 warning signs

No single metric tells the full story. See the MIL:1INSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Insmed Business Description

Other Exchanges INSM:USA0JAV:UKIM8N:Germany
Address 700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
45GF Score

Get the complete analysis for MIL:1INSM

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€86.10
Price
€160.63
GF Value